Osteonecrosis of the jaw under palbociclib: A case series description
- 22 March 2023
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (8) , 1990-1997
Abstract
Introduction: Cases of osteonecrosis of the jaw have been reported by dental surgeons to the pharmacovigilance center in Rennes, France, occurring among patients treated with palbociclib, a cyclin-dependent kinase 4/6 inhibitor. Although this event was not expected with the drug, a safety signal was raised. Describing a local case series, the aim of our study was to identify specific patterns that might suggest a triggering role for these drugs, and to discuss pathophysiological hypotheses. Materials and methods: A retrospective case series of patients exposed to cyclin-dependent kinase 4/6 inhibitors between 2016 and 2020 with a diagnosis of osteonecrosis of the jaw at the Rennes Dental Care Center was analyzed. The descriptive analysis was conducted on patient demographics, breast cancer characteristics, osteonecrosis of the jaw, biological data, and exposure to cyclin-dependent kinase 4/6 inhibitors. Results: We identified eight cases, most of them at stages 0–1 (62.5%). Four patients were still exposed to palbociclib at the time of diagnosis and four had discontinued the treatment before the diagnosis. Chronological imputability could not be excluded given the drug’s half-life and the variable intervals of dental monitoring from one patient to another. All patients had at least one dental osteonecrosis risk factor (including dental extraction, dentures, and denosumab exposure at the time of diagnosis). Neutropenia and mucositis were not systematically reported at the time of diagnosis. The anatomopathological characteristics were nonspecific. Conclusion: We did not identify a specific pattern that could suggest a triggering role of palbociclib in the development of ONJ.Keywords
This publication has 34 references indexed in Scilit:
- Palbociclib and Letrozole in Advanced Breast CancerNew England Journal of Medicine, 2016
- Osteonecrosis of the Jaw—a Bone Site-Specific Effect of BisphosphonatesCurrent Osteoporosis Reports, 2016
- Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)The Oncologist, 2016
- Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18Breast Cancer Research, 2016
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialThe Lancet Oncology, 2016
- Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase InhibitorJAMA Oncology, 2016
- Medication‐Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic ApproachesStem Cells International, 2016
- Infection and Medication-related Osteonecrosis of the JawJournal of Dental Research, 2015
- Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trialsClinical Oral Implants Research, 2015
- American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 UpdateJournal of Oral and Maxillofacial Surgery, 2014